Hib meningococcal group C vaccine - GlaxoSmithKline

Drug Profile

Hib meningococcal group C vaccine - GlaxoSmithKline

Alternative Names: Hib-MenC conjugated vaccine - GlaxoSmithKline; Hib-MenC vaccine - GSK Biologicals; Hib-MenC-TT; Hib-MenC-TT conjugated vaccine - GlaxoSmithKline; HibMenC; Menitorix

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections; Meningococcal group C infections

Most Recent Events

  • 01 Nov 2012 GlaxoSmithKline completes a phase III trial in Haemophilus infections and Meningococcal group C infections (prevention, in treatment-experienced children) in Germany, Poland and Spain (NCT00891176)
  • 19 Feb 2010 GlaxoSmithKline completes a phase III trial evaluating its immunogenicity and safety in preterm infants in Spain
  • 18 Aug 2006 First global launch of Menitorix™ in the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top